Alemtuzumab for Chronic Lymphocytic Leukemia
Author Information
Author(s): Fraser G., Smith C.A., Imrie K., Meyer R.
Primary Institution: Cancer Care Ontario’s Program in Evidence-Based Care
Hypothesis
Is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia?
Conclusion
Alemtuzumab is a reasonable treatment option for patients with progressive and symptomatic chronic lymphocytic leukemia that is refractory to both alkylator-based and fludarabine-based regimens.
Supporting Evidence
- A systematic review found no published randomized controlled trials evaluating alemtuzumab alone for chronic lymphocytic leukemia.
- Patients receiving alemtuzumab had significantly improved progression-free survival compared to those undergoing observation.
- The overall response rate for alemtuzumab was 38% in single-arm studies.
Takeaway
Alemtuzumab can help some patients with a type of blood cancer called chronic lymphocytic leukemia, but it can also cause serious side effects.
Methodology
A systematic review of multiple databases was conducted to gather evidence on alemtuzumab for chronic lymphocytic leukemia.
Potential Biases
Potential bias due to the lack of randomized controlled trials and reliance on observational data.
Limitations
The evidence is primarily from case series and lacks robust randomized controlled trials.
Participant Demographics
Adult patients with B-cell chronic lymphocytic leukemia.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website